{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:27:15Z","timestamp":1779114435682,"version":"3.51.4"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1097\/js9.0000000000004060","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:00:25Z","timestamp":1765983625000},"page":"1891-1893","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trial landscape of cellular therapies in bladder cancer"],"prefix":"10.1097","volume":"112","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangwu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20260518","first-page":"209\u201349","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"90521\u201331","DOI":"10.18632\/oncotarget.19361","article-title":"Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"R3-20260518","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s42003-024-06917-9","article-title":"STAT1 as a tool for non-invasive monitoring of NK cell activation in cancer","volume":"7","author":"Min","year":"2024","journal-title":"Commun Biol"},{"key":"R4-20260518","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"R5-20260518","article-title":"Overcoming the quality gap in clinical trial landscape analysis: paving the way for impactful research","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"R6-20260518","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R7-20260518","doi-asserted-by":"crossref","first-page":"2419\u201331","DOI":"10.1038\/s41375-025-02710-7","article-title":"Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias","volume":"39","author":"Tirtakusuma","year":"2025","journal-title":"Leukemia"},{"key":"R8-20260518","first-page":"101200JCO2500765","article-title":"C-144-01 investigators. long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","author":"Medina","year":"2025","journal-title":"J Clin Oncol"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"3112\u201317","DOI":"10.1158\/1078-0432.CCR-25-0595","article-title":"FDA approval summary: afamitresgene autoleucel for adults with HLA-restricted MAGE-A4 positive unresectable or metastatic synovial sarcoma after prior chemotherapy","volume":"31","author":"Barnett","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"540\u201359","DOI":"10.1016\/j.trecan.2025.02.007","article-title":"Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside","volume":"11","author":"Luo","year":"2025","journal-title":"Trends Cancer"},{"key":"R11-20260518","doi-asserted-by":"crossref","first-page":"1002288","DOI":"10.37349\/etat.2025.1002288","article-title":"Neoantigen immunotherapy: a novel treatment for bladder cancer","volume":"6","author":"Lv","year":"2025","journal-title":"Explor Target Antitumor Ther"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:15:30Z","timestamp":1779110130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004060","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"2025-08-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}